Administration of sorafenib to MC38 subcutaneous tumors also presented impaired tumor growth (Fig. 6F) and size (Fig. 6G & H) in dose-dependent manner, as determined by Ki-67 staining (Fig. 6I-K), whereas sorafenib show no significant effect in negative control tumors (Fig. 6L-N), demonstrating its specific curative effect to STOML2-overexpressed CRC tumors in vivo. The gene discussed is MKI67; the disease is neoplasm.